Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit
Abstract Alzheimer’s disease (AD) diagnosis relies on cerebrospinal fluid (CSF) biomarkers or amyloid PET. Alternatives for AD diagnosis from blood samples are needed to develop a fully-automated early-diagnosis approach, potentially implemented in a cognitive disorder unit. Plasma p-Tau217 was dete...
Saved in:
| Main Authors: | Lourdes Álvarez-Sánchez, Carmen Peña-Bautista, Laura Ferré-González, Ángel Balaguer, Julián Luis Amengual, Miguel Baquero, Consuelo Cháfer-Pericás |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-01511-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer’s disease in a tertiary memory clinic
by: Javier Arranz, et al.
Published: (2025-07-01) -
Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platformResearch in context
by: Azadeh Feizpour, et al.
Published: (2024-11-01) -
Early cerebrospinal fluid elevations of pTau-217 in severe traumatic brain injury subjects
by: Hamad Yadikar, et al.
Published: (2025-07-01) -
Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217
by: Giulia Musso, et al.
Published: (2025-08-01) -
Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse® platform
by: Marcella Catania, et al.
Published: (2025-01-01)